10x Genomics Stock (TXG:NSD) Analysis:
Last Closing Price: $34.93
Consensus Analyst Rating: Hold
12-Month Price Target: $51.73
Market CAP: $4.00 Billion
10 analysts now covering 10x Genomics stock (TXG:NSD) have given the stock a consensus recommendation of “Hold”. 2 research analysts have assigned the stock a “Sell” rating, 1 has issued a “Hold” rating, and 3 have assigned a “Buy” rating to the 10x Genomics stock.
The average 12-month price target among analysts who have recently updated coverage on the stock is $51.73.
10x Genomics Stock-Analyst Ratings:
Recently, a number of research firms have weighed in on TXG stock.
Morgan Stanley dropped their price target on shares of 10x Genomics from $70.00 to $64.00 and assigned the stock an “Overweight” rating.
Cowen boosted their price objective on shares of 10x Genomics to $55.00.
Goldman Sachs Group lowered their price objective on shares of 10x Genomics from $35.00 to $25.00 and assigned the stock a “sell” rating.
JPMorgan Chase & Co. cut their price objective on shares of 10x Genomics stock from $65.00 to $55.00.
In related news, 10x Genomics CEO Serge Saxonov sold 2,676 shares of the company’s stock on Tuesday, November 22. At an average price of $34.07, the shares were sold for a total of $91,171.32. Following the sale, the chief executive officer now directly owns 974,926 shares of the company worth $33,215,728.82.
Additionally, Chief Financial Officer Justin J. Mcanear sold 1,626 shares of 10x Genomics stock on Tuesday, November 22. The shares were sold at an average price of $34.07 per share, totaling $55,397.82 in revenue. The chief financial officer now owns 76,764 shares of the 10x Genomics stock worth $2,615,349.48 after the sale. Insiders sold 6,663 shares of company stock worth $227,008 over the past ninety days.
The company’s insiders hold 11.08% of its stock.
Recently, hedge funds and other institutional investors have altered their stakes in the company.
In the second quarter, SRS Investment Management LLC increased its holdings in 10x Genomics by 1,214.3%. SRS Investment Management LLC now owns 2,758,245 shares of the company’s stock valued at $124,811,000 after purchasing an additional 2,548,380 shares in the preceding quarter.
FMR LLC increased its holdings of 10x Genomics by 50.2% during the second quarter. FMR LLC now owns 6,195,527 shares of the company’s stock worth $280,347,000 after acquiring an additional 2,070,318 shares during the last quarter.
In the first quarter, Sands Capital Management LLC increased its holdings in 10x Genomics by 92.4%. Sands Capital Management LLC now owns 3,201,394 shares of the company’s stock valued at $243,530,000 after purchasing an additional 1,537,424 shares in the last recent quarter.
In the first quarter, BlackRock Inc. increased its holdings in 10x Genomics by 14.2%. BlackRock Inc. now holds 9,156,992 shares of the company’s stock, valued at $696,572,000, after acquiring an additional 1,138,358 shares in the last recent quarter.
Finally, Baillie Gifford & Co. boosted its investment in 10x Genomics by 13.9% in the second quarter. Baillie Gifford & Co. now owns 8,378,971 shares of the company’s stock worth $379,148,000 after acquiring an additional 1,023,207 shares during the last quarter.
Institutional investors and hedge funds hold 74.10% of the 10x Genomics stock shares.
5% Fall in 10x Genomics Stock Price:
TXG opened at $34.93 on Monday. The firm’s market capitalization is $4 billion, its price-to-earnings ratio is -23.60, and its beta is 1.70.
10x Genomics has a 52-week low of $23.81 and a 52-week high of $154.10. The company’s fifty-day simple moving average is $32.09, while its two-hundred-day simple moving average is $37.17.
Quarterly Earnings Overview:
10x Genomics (TXG:NSD) last posted its quarterly earnings data on Wednesday, November 2nd. The company announced quarterly earnings per share of ($0.37), $0.09 better than the consensus expectation of ($0.46).
The business had revenue of $131.10 million for the quarter, compared to the consensus estimate of $129.13 million. 10x Genomics’ net margin was negative at 33.20 percent, and its return on equity was negative at 21.01 percent.
Compared to the same quarter previous year, the company’s revenue increased 4.6%. During the same period previous year, the company produced earnings per share of ($0.15) On average, analysts anticipate that 10x Genomics will report -1.61 EPS for the current fiscal year.
About 10X Genomics Inc. (TXG:NSD):
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets.
The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence.
It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014.
10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.